Ramzi Dagher, MD

Articles

Liposomal Doxorubicin in Combination With Bortezomib for Relapsed or Refractory Multiple Myeloma

Yang-Min Ning, MD, PhD;Kun He, PhD;Ramzi Dagher, MD;Rajeshwari Sridhara, PhD;Ann Farrell, MD;Robert Justice, MD;Richard Pazdur, MD

November 1st 2007

Liposomal doxorubicin received FDA approval for use in combination with bortezomib in patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

Topotecan in Combination With Cisplatin for the Treatment of Stage IVB, Recurrent, or Persistent Cervical Cancer

Michael Brave, MD;Ramzi Dagher, MD;Ann Farrell, MD;Sophia Abraham, PhD;Roshni Ramchandani, PhD;Jogarao Gobburu, PhD;Brian Booth, PhD;Xiaoping Jiang, PhD;Rajeshwari Sridhara, PhD;Robert Justice, MD;Richard Pazdur, MD

October 1st 2006

Topotecan, a camptothecin analog previously approved for the treatment of ovarian cancer and small-cell lung cancer, was granted regular approval by the US Food and Drug Administration (FDA) on June 14, 2006, for use in combination with cisplatin to treat women with stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. The purpose of this summary is to review the database supporting this approval.